Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2014
Reporting Period: Events occurring between May 22, 2014, and June 4, 2014.
Key Financial Metrics and Capital Activities
This filing reports unregistered sales of equity securities and debt conversions rather than standard operating financial metrics. The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt levels.
- Equity Issuance (May 22 - June 4, 2014): 1,500,000 shares of common stock issued for an aggregate purchase price of $375,000.
- Warrants Issued:
- 125,000 warrants at an exercise price of $0.75 per share.
- 250,000 warrants at an exercise price of $0.30 per share.
- Term: Five years.
- Debt Conversion (May 2014): 379,329 shares of common stock issued in exchange for $80,000 of outstanding indebtedness (including $5,000 in accrued and unpaid interest).
Material Changes
The primary material change is the increase in outstanding common stock and the reduction of outstanding indebtedness through the transactions described above. The company raised $375,000 in cash and extinguished $80,000 in debt obligations during the reported period.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure regarding the unregistered nature of the securities. The company relied upon Section 4(a)(2) of the Securities Act of 1933, asserting that the transactions did not involve a public offering and were made to a limited number of accredited investors without general solicitation.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the current status of the $80,000 debt extinguished via the May 2014 conversion.
- Review the terms of the newly issued warrants (exercise prices and expiration) for potential future dilution.
- Check subsequent filings for any updates on the company's liquidity position following these capital raises.